Orlon,

OPC sums it up well below (above). For the last 2 years MannKind has been marshaling all of its' resources to survive a $250 million delay from the FDA. The last thing we need is another orifice bleeding red ink currently IMO. As the FDA goes, Euro approvals will go. If the drug is as Al believes we will have a hard enough time getting additional filling pods to expand to the capacity needed to keep ahead of the demand curve. The manufacturing of engineered devices takes months to complete and weeks to ship from Germany. Imagine how devastating it would be if after approval MannKind was not able to fill prescriptions due to a backlog of orders....

Now on the other hand if the interest in the Middle East from the "small country which wants to buy $200 million worth of product" is a real deal, bring it on.